We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Human Irisin Concentration in Sarcopenia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01874912
First Posted: June 11, 2013
Last Update Posted: June 11, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
K. M. Choi, Korea University
  Purpose
Irisin has been identified as a novel myokine that drives brown-fat-like conversion of white adipose tissue. In this cross-sectional study, the researches investigated whether serum irisin levels are decreased in patients with sarcopenia compared with control subjects with normal muscle mass, and assessed the association between serum irisin levels and various metabolic parameters.

Condition
Sarcopenia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional

Further study details as provided by K. M. Choi, Korea University:

Primary Outcome Measures:
  • Serum concentration of irisin in the subjects with sarcopenia [ Time Frame: 12 week ]

Secondary Outcome Measures:
  • The relationship of serum irisin levels with lipid profiles [ Time Frame: 12 week ]
  • The relationship of serum irisin levels with skeletal muscle mass index [ Time Frame: 12 wks ]

Enrollment: 406
Study Start Date: November 2009
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients in Korean Sarcopenic Obesity Study (KSOS), an prospective observational cohort study designed to examine the prevalence of sarcopenia and sarcopenic obesity in Korean adults and to evaluate their effects on metabolic disorders and health outcomes.
Criteria

Inclusion Criteria:

  • 20<age<80
  • apparently healthy subjects

Exclusion Criteria:

  • a history of cardiovascular disease
  • diabetes
  • stage 2 hypertension
  • malignancy
  • severe renal or hepatic disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01874912


Locations
Korea, Republic of
Korea University Guro Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Korea University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: K. M. Choi, Professor, Korea University
ClinicalTrials.gov Identifier: NCT01874912     History of Changes
Other Study ID Numbers: SO(IRISIN)
First Submitted: June 3, 2013
First Posted: June 11, 2013
Last Update Posted: June 11, 2013
Last Verified: June 2013

Additional relevant MeSH terms:
Sarcopenia
Muscular Atrophy
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Atrophy
Pathological Conditions, Anatomical
Signs and Symptoms